News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,686 Results
Type
Article (14301)
Company Profile (105)
Press Release (260272)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (88382)
Career Advice (466)
Deals (15408)
Drug Delivery (73)
Drug Development (37006)
Employer Resources (50)
FDA (6427)
Job Trends (6254)
News (151132)
Policy (14170)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (449)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (23350)
ALS (56)
Alzheimer's disease (490)
Antibody-drug conjugate (ADC) (100)
Approvals (6624)
Artificial intelligence (201)
Autoimmune disease (39)
Automation (12)
Bankruptcy (150)
Best Places to Work (4408)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (40)
Bladder cancer (45)
Brain cancer (31)
Breast cancer (172)
Cancer (1352)
Cardiovascular disease (152)
Career advice (419)
Career pathing (13)
CAR-T (49)
CDC (6)
Cell therapy (152)
Cervical cancer (9)
Clinical research (32279)
Collaboration (729)
Compensation (325)
Complete response letters (33)
COVID-19 (825)
CRISPR (43)
C-suite (432)
Cystic fibrosis (58)
Data (1859)
Denatured (18)
Depression (45)
Diabetes (129)
Diagnostics (1393)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (113)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (82)
Earnings (33532)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39085)
Executive appointments (528)
FDA (7548)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (429)
Gene editing (71)
Generative AI (18)
Gene therapy (166)
GLP-1 (439)
Government (1410)
Grass and pollen (4)
Guidances (164)
Healthcare (3603)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (68)
Immuno-oncology (14)
Indications (53)
Infectious disease (890)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (27)
Intellectual property (113)
Interviews (61)
IPO (5923)
IRA (33)
Job creations (2056)
Job search strategy (374)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (206)
Leadership (8)
Legal (3454)
Liver cancer (24)
Longevity (8)
Lung cancer (192)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (415)
MASH (67)
Medical device (1318)
Medtech (1325)
Mergers & acquisitions (9905)
Metabolic disorders (437)
Multiple sclerosis (50)
NASH (14)
Neurodegenerative disease (84)
Neuropsychiatric disorders (37)
Neuroscience (904)
Neurotech (1)
NextGen: Class of 2026 (1591)
Non-profit (604)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (109)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (121)
Peanut (12)
People (29760)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8374)
Phase 2 (13642)
Phase 3 (12302)
Pipeline (1922)
Policy (135)
Postmarket research (1408)
Preclinical (3354)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (135)
Rare diseases (351)
Real estate (2659)
Recruiting (18)
Regulatory (11009)
Reports (15)
Research institute (582)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (80)
Series B (48)
Service/supplier (2)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1646)
State (2)
Stomach cancer (5)
Supply chain (50)
Tariffs (68)
The Weekly (45)
Vaccines (239)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Last 7 days (177)
Last 30 days (683)
Last 365 days (10489)
2026 (959)
2025 (10792)
2024 (12592)
2023 (14352)
2022 (19694)
2021 (20195)
2020 (19098)
2019 (14935)
2018 (11734)
2017 (13931)
2016 (13161)
2015 (15498)
2014 (12421)
2013 (10596)
2012 (11405)
2011 (11930)
2010 (10900)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20920)
Australia (2707)
California (3201)
Canada (1483)
China (555)
Colorado (143)
Connecticut (129)
Delaware (134)
Europe (40999)
Florida (602)
Georgia (65)
Hawaii (1)
Idaho (10)
Illinois (348)
India (44)
Indiana (240)
Iowa (2)
Japan (247)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (428)
Massachusetts (2594)
Michigan (47)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (19)
New Hampshire (11)
New Jersey (1430)
New Mexico (7)
New York (919)
North Carolina (619)
North Dakota (2)
Northern California (1462)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (723)
Puerto Rico (12)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1391)
Tennessee (53)
Texas (458)
United States (12782)
Utah (59)
Virginia (160)
Washington D.C. (42)
Washington State (224)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
274,686 Results for "sequel pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, announced its partner, DEKA Research & Development Corp., has received 510 clearance from the U.S. Food and Drug Administration for the innovative twiist™ Automated Insulin Delivery system powered by Tidepool.
March 18, 2024
·
4 min read
Press Releases
Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone Sensor
May 22, 2025
·
3 min read
Press Releases
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
April 29, 2025
·
7 min read
FDA
Sequel Spiral™ Tampon Receives FDA Approval as Medical Device
Sequel, a startup, dedicated to engineering better health and wellness experiences for women, today announced that its breakthrough spiral tampon has received approval from the United States Food and Drug Administration (FDA) as a medical device.
August 15, 2023
·
3 min read
Pharm Country
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
October 24, 2023
·
7 min read
Press Releases
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
August 23, 2024
·
8 min read
Drug Development
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics, Inc. today announced topline results from its Phase 2 double-blind, single-crossover SEQUEL study (NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.
June 28, 2023
·
10 min read
Drug Development
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
Cognition Therapeutics, Inc. announced that it will host a conference call and webcast on June 28, 2023, at 8:00am ET to discuss topline results from its Phase 2 SEQUEL Study for mild-to-moderate Alzheimer’s disease.
June 27, 2023
·
5 min read
Drug Development
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s DiseaseInnovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction
Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that enrollment has completed in the randomized, double-blind Phase 2 SEQUEL study (COG0202, NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.
February 9, 2023
·
7 min read
Pharm Country
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease.
September 27, 2022
·
5 min read
1 of 27,469
Next